Patent law shift tilts enforcement toward inventors—and away from generic competition

What it does

This bill amends patent law to create a legal presumption that courts should grant permanent injunctions (court orders stopping infringement) when a patent owner wins an infringement case, unless the defendant can rebut that presumption with equitable defenses. The bill aims to restore what Congress characterizes as the historical practice of presumptive injunctions, which it argues has been eroded by recent court decisions, and to protect patent owners—especially individual inventors, universities, startups, and small businesses—from continued infringement by large companies.

Why we flagged it

The bill's operative mechanism is a single, clearly stated change to patent remedies law: it restores a rebuttable presumption of injunctive relief upon infringement judgment. This is a straightforward doctrinal shift in patent litigation procedure, not a hidden rider or concealed benefit.

What the text implies

• Presumptive injunctions may increase settlement leverage for patent holders, potentially leading to higher licensing fees and royalties that flow through to consumer prices for patented products and services.
• Small patent holders and universities may gain enforcement power, but the bill does not distinguish between legitimate patents and low-quality or overly broad patents—all infringement judgments trigger the presumption equally.
• Increased injunction risk may deter generic drug manufacturers and competitors from entering markets, potentially delaying or preventing price competition in pharmaceuticals and other patent-heavy sectors.
• The bill does not address patent trolls or non-practicing entities; a troll holding a broad patent could use the presumption to extract settlements from legitimate competitors without producing anything.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill strengthens patent enforcement for individual inventors and small entities, which may spur innovation and protect undercapitalized creators. However, it may also increase litigation costs, raise prices for consumers (if patent holders can more easily block competitors), and reduce access to generic or competing products—effects that fall on ordinary people as consumers and patients.

Who stands to gain

• patent holders (individual inventors, universities, startups, small/medium enterprises)
• patent licensing firms and patent aggregators
• pharmaceutical companies holding patent portfolios
• technology companies with large patent portfolios

Named in the bill

35 U.S.C. § 283, patent owners, individual inventors, institutions of higher education, startups, small and medium-sized enterprises, large multinational companies, U.S. courts

Where it stands

5 cosponsors: 4 Democrats, 1 Republicans.

• Feb 25, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 25, 2025 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

18 lobbying clients named this bill on 25 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $26,806,909 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 96% of bills with at least one filing.

Nathaniel Moran, the sponsor, reported $856,691 in PAC receipts in the 2026 cycle. $17,000 of that came from 2 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $8,410,000 on 1 filing
• Amazon.com Services LLC — $4,360,000 on 1 filing
• Dell Technologies Inc — $2,970,000 on 2 filings
• Apple Inc — $2,740,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.